SCHEMBL2554711

SCHEMBL2554711

Cc1sccc1-c1ccc(C(=O)Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.43
PLA2G10 O15496 1/20 0.38
ALDH1A1 P00352 2/20 0.35
BCAT2 O15382 1/20 0.35
PTGS2 P35354 2/20 0.34
RXFP1 Q9HBX9 2/20 0.34
RORB Q92753 1/20 0.34
HSD17B1 P14061 1/20 0.33
PRKCZ Q05513 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GSK3B P49841 1/20 0.33
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2040391 0.84 RXRA (0.47) PTGS1ALDH1A1TSHRHSD17B10KDM4E
SCHEMBL2552781 0.75 CYP2A6 (0.44) PTGS1GSK3B
SCHEMBL8089263 0.74 PTGS2 (0.49) PTGS1PLA2G10ALDH1A1PTGS2MAPT
SCHEMBL695291 0.71 PTGS1 (0.51) PTGS1PTGS2PRKCZ
SCHEMBL727046 0.71 ALDH1A1 (0.52) ALDH1A1HSD17B1MAPTTSHRGSK3B
SCHEMBL10670934 0.71 ALDH1A1 (0.52) ALDH1A1HSD17B1MAPTTSHRGSK3B
SCHEMBL4251313 0.70 CA12 (0.49) HSD17B1MKNK1MKNK2
SCHEMBL30876050 0.70 ALDH1A1 (0.43) PTGS1ALDH1A1BCAT2PTGS2MAPT
SCHEMBL6668626 0.70 ALDH1A1 (0.54) ALDH1A1GSK3BGAAHTTRAB9A
SCHEMBL1825367 0.70 BCAT2 (0.47) ALDH1A1BCAT2PTGS2RXFP1PRKCZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200125564-A1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS OGEDA SA (BE) 2020-04-23 US disclosed
EP-3176171-A1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS OGEDA SA (BE) 2017-06-07 EP disclosed
EP-2552920-B1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS OGEDA SA (BE) 2017-03-15 EP disclosed
EP-2552920-A1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS Euroscreen S.A. (BE) 2013-02-06 EP disclosed
WO-2011121137-A1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS EUROSCREEN S.A. (BE) 2011-10-06 WO disclosed